Home
overview

If you are interested in presenting at the 2010 summit, please click here to submit a speaking proposal for review.

 

Pharmaceutical companies are facing the evolution of drug discovery, hence moving from traditional drugs to biopharmaceuticals. Proteins are used widely in the formulation of these drugs and have potential as therapeutic targets. With the understanding of a protein's structure, it is possible to engineer a target protein that would either inhibit or deactivate the reaction and prevent the disease or destroy it. This requires new, more efficient methods to identify and analyse proteins involved in disease populations, with the aim to discover novel diagnostic tools and required drugs for treatments.

SMi’s 5th annual Global Protein Summit aims to cover needs and developments within the industry. This is an excellent opportunity to network and learn about new developments from leaders in Protein Expression, Functional analysis and Purification.

  • PROTEIN EXPRESSION TECHNOLOGIES: Learn about novel technologies developed and used for a variety of compounds.
  • HIGH-THROUGHPUT PURIFICATION AND ANALYSIS: Discover how industry leaders process proteins and increase solubility through key experiences and case studies.
  • STRUCTURAL RESEARCH: Learn about new advances in biotherapeutics and other structural studies.
  • FORMULATION AND CHARACTERISATION OF BIOTHERAPEUTICS: Gain insight into developments and the future of biotherapeutic formulation.
  • NETWORKING OPPORTUNITIES: Meet leaders in the field, make valuable contacts and learn from their experience and expertise. 

 Vice Presidents, Directors and Heads of:

  • Protein expression / Purification Biochemistry
  • Proteomics
  • Gene expression
  • Medical Affairs
  • Clinical Affairs
  • Scientific Affairs
  • Drug Surveillance/
  • Product Safety
  • Regulatory Affairs
  • Pharmacovigilance 
Last year's attendees included representatives of the following companies:
 
  • Roche Diagnostics GmbH
  • GlaxoSmithKline
  • Bayer-Schering Pharma                        
  • Boehringer Ingelheim Pharma
  • Actelion Pharmaceuticals Ltd
  • Labotatorios Almirall
  • Vertex Pharmaceuticals
  • Syngenta
  • Pfizer                                                                           
  • Evotec OAl
  • Roche Products Ltd
  • Merck Research Labs
  • Wyeth Research
  • UCB Celltech
  • AstraZeneca                             

Conference programme

8:30 Registration & Coffee

9:00 Chairman's opening remarks

Ian Hunt

Ian Hunt, Group Leader, Novartis

9:10 FROM DNA TO PROTEIN ON A FULLY AUTOMATED PLATFORM

Lori Jennings

Lori Jennings, Research Investigator II, Protein Sciences, Genomics Institute Of The Novartis Research Foundation

 
  •  Protein Expression and Purification Platform (PEPP): Custom engineered robotics to support protein production for research and drug discovery
  •  Providing automated cell culture, transfection/infection, harvest and purification at a scale of 35-mL per sample
  •  Secreted, intracellular, and membrane proteins can be harvested and purified
  •  PEPP system enables (i) screening large numbers of constructs, (ii) screening constructs in multi-matrix conditions for expression-purification, and (iii) small scale protein production for HTP bioassays
  •  

    9:50 SCLEROSTIN: A POTENTIAL NEW TARGET FOR TREATING LOW BONE MASS DISORDERS

    Alistair Henry

    Alistair Henry, Senior Principal Scientist, UCB-Celltech

  • Protein production
  • Proteins Structure solution
  •  Antibody generation and selection
  • 10:30 Morning Coffee

    11:00 EFFICIENT STRATEGIES FOR PROCESS DEVELOPMENT AND PROTEIN PRODUCTION FOR DIAGNOSIS SCREENING AND THERAPEUTICAL APPLICATIONS

    Sabrina Guillemer

    Sabrina Guillemer, Expression Group Leader, Proteus

  • Cell based and cell-free multi host expression profiling
  • Flexible production and purification strategies
  • Process development
  • 11:40 OPTIMISING EXPRESSION OF MAMMALIAN PROTEINS FOR INTERACTION STUDIES

    Michael Dyson

    Michael Dyson, Senior Research Associate, University of Cambridge

  • Rational and combinatorial protein engineering methods to improve the expression of large multi-domain proteins in E. coli and mammalian cells
  • Multiplexing expression in HEK293E cells
  • Generation of a large murine cell-surface receptor ectodomain expression library and its use for both antibody production and discovery of novel receptor interactions
  • Methods to convert single chain antibodies to full IgG antibodies
  • 12:20 Networking lunch

    13:50 PROTEIN EXPRESSION USING A NOVEL SUMO SYSTEM

    Jeffrey Marblestone

    Jeffrey Marblestone, Senior Scientist, Progenra

  • Universal Platform for Protein Expression in Prokaryotes and Eukaryotes
  • Exploring SUMO; from an essential modification in the cell to the advancement of protein production in the lab
  • SUMO fusion tags enhance protein expression in prokaryotic cells
  • Applications of engineered SUMO (SUMOstar) to enhance eukaryotic protein expression
  • Universal SUMO system, Ligation Independent Cloning for Rapid Expression in E. coli, yeast, Insect and Mammalian Cells
  • Therapeutic protein expression and superiority of SUMO system
  • 14:30 MEMBRANE TRANSPORT PROTEINS – FROM GENE TO STRUCTURE

    Peter Henderson

    Peter Henderson, Coordinator, European Drug Initiative for Ion Channels and Transporters, University of Leeds

  • Bacterial homologues of human transport proteins
  • Cloning, expression and purification
  • Assessing activities of purified proteins
  • Stability trials
  • Recent structures determined by X-ray crystallography
  • 15:10 Afternoon tea

    15:40 PROTEINS AS TARGETS & THERAPEUTICS:

    Mark Swindells

    Mark Swindells, Managing Director, Ebisu

  • Chemogenomics research
  • GPCR targets 
  • Monoclonal Antibody therapeutics
  • 16:20 CONCEPT TO CLINIC WITH RECOMBINANT ANTIBODY-BASED FUSION PROTEINS

    Kerry Chester

    Kerry Chester, Professor, UCL Cancer Institute

  • Design criteria for scFv-based cancer treatments
  • Cancer imaging and therapy with scFvs, fusion proteins and nanoparticles.
  • GMP production of engineered antibody fragments in a research institute
  • Bench-to-bedside case study with a multifunctional antibody-enzyme fusion protein for targeted cancer therapy

  • 17:00 Chairman’s closing remarks and close of day one

    8:30 Registrations & Cofee

    9:00 Chairman's Opening Remarks

    Trevor Wilkinson

    Trevor Wilkinson, Head of Protein Sciences, Medimmune Cambridge

    9:10 DISCOVERING BIOLOGICAL THERAPEUTICS: ADVANCING THE DRUG DISCOVERY PROCESS FOR OPTIMAL LEAD SELECTION

    Trevor Wilkinson

    Trevor Wilkinson, Head of Protein Sciences, Medimmune Cambridge

  • Generating molecular targets (antigens)
  • Exploring the combined use of phage display and high throughput assay technologies to identify antibodies
  • Engineering pM affinity antibodies by the use of phage and ribosome display
  • Examining case studies of engineering potential antibody therapeutics
  • Sharing insights into the structural basis of antibody-antigen recognition derived from co-crystal structures
  • 9:50 MULTI-PARALLEL RECOMBINANT PROTEIN PRODUCTION

    Stephen Hammond

    Stephen Hammond, Chief Executive Officer, Scottish Biomedical Foundation

  • Matching productive parallel vectors, to appropriate expression systems
  • How to use these in parallel to produce high fidelity recombinant proteins within the shortest time
  • Rapid identification of appropriate purification strategies: Small, medium and large scale
  • Parallel expressions of multiple proteins – Challenges 
  • Validation strategies and solutions
  •  

    10:30 Morning Coffee

    11:00 OVERCOMING THE CHALLENGES OF PROTEIN PRODUCTION

    Ian Hunt

    Ian Hunt, Group Leader, Novartis

  • Instrumentation to expedite identification of soluble proteins - multi-parallel expression profiling, fast or fiction
  • Tricks of the trade - a review of technologies and methodologies that enhance insect mediated baculovirus and E.coli protein expression
  • Looking forward – what are the challenges and trends facing protein sciences?
  • The presentation will use a series of case studies from a number of different drug targets to illustrate the impact of the various approaches in expediting protein delivery for pharma/biotech discovery
  • 11:40 RATIONAL DESIGN OF ANTIBODIES FOR THE INHIBITION OF GASTRIN ACTIVITY IN PANCREATIC CANCER

    Ignacio Casal

    Ignacio Casal, Biotechnology Programme Director and Head of the Protein Technology Unit, CIB.CSIC

  • Gastrin and derivatives are becoming important targets for immunotherapy of pancreatic, gastric and colorectal tumors
  • We have combined different strategies to generate a wide array of human and mouse antibodies against gastrin.
  •  Using scFvs to delineate the gastrin epitopes and their functional significance for the blocking of gastrin trophic effects on tumoral cells
  •  Combining CDR3 walking randomisation and “in silico” rational design-based to enhance the affinity of the human anti-gastrin scFvs expressed in E.coli
  • Potential benefits of the expression of scFv antibodies in E.coli for therapeutic design will be discussed
  •  

    12:20 Networking lunch

    13:50 PROTEIN PRODUCTION IN INDUSTRY

    Richard Bazin

    Richard Bazin, Senior Principle Scientist, Pfizer

  • Proteins for crystallisation
  • Membrane proteins
  • Production and immobilisation of proteins for SPR measurements
  • 14:30 APPLICATION OF THE CELL-FREE PROTEIN PRODUCTION SYSTEM TO GENOME-WIDE SCREENING FOR MAPPING PROTEIN NETWORKS AND FOR DISCOVERING BIOMARKERS AND DRUGS

    Yaeta Endo

    Yaeta Endo, Executive Director, Ehime University

  • Substrate screening of protein kinases and proteases
  • Screening of autoantigens for biomarker discovery
  • Discovery of malaria vaccine candidates
  • Production and assay of HIV proteases from mutant genes of patients for selecting effective drugs
  • 15:10 Afternoon tea

    15:40 SAFETY AND IMMUNOGENICITY OF PROTEINS

    Tim Jones

    Tim Jones, Research Director, Antitope

  • Designing therapeutic drugs with reduced immunogenicity
  • Explanation of immunogenicity risk factors
  • The importance of T cell epitopes in driving immunogenicity
  • Accurate detection of T cell epitopes using in vivo T cell assays
  • Strategies to re-engineer proteins as a way of reducing immunogenicity
  • 16:20 HIGH YIELD PRODUCTION OF AN E.coli I EXPRESSED SOLUBLE Fc RECEPTOR WITH BIOLOGICAL ACTIVITY

    Peter Sondermann

    Peter Sondermann, CSO, SuppreMol

    <ul> <li><font size="1">Development of a first-in-class therapeutic for the treatment of autoimmune diseases</font></li> <li><font size="1">Soluble Fc Receptors (sFcRs)&nbsp;as immune modulating proteins with high therapeutic potential</font></li> <li><font size="1">Expression of sFcRs in E.coli as inclusion bodies and subsequent efficient refolding&nbsp;to allow&nbsp;production in high yields</font></li> <li><font size="1">Ligand binding properties of the refolded material is comparable to that of mammalian expressed versions</font></li> <li><font size="1">Demonstrating biological activity of sFcRs in several murine models of human autoimmune diseases</font></li> </ul>

    17:00 Chairman’s closing remarks and close of conference

    +

    Workshops

    Difficult to Express Proteins
    Workshop

    Difficult to Express Proteins

    Copthorne Tara Hotel
    3rd June 2009
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.